Results 181 to 190 of about 71,769 (253)

Sinusoidal Obstruction Syndrome With Inotuzumab Ozogamicin Combined With Ponatinib for Philadelphia‐Chromosome‐Positive Lymphoblastic Malignancies

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Introduction Sinusoidal obstruction syndrome, also known as veno‐occlusive disease (SOS/VOD), can occur after exposure to inotuzumab ozogamicin (InO), a calicheamicin‐based antibody‐drug conjugate. Case Presentation We experienced two cases of SOS/VOD after treatment with InO combined with intermittent administration of ponatinib without ...
Emi Yokoyama, Satoshi Ota, Yasuo Sakurai, Toma Suzuki, Naoki Miyashita, Minoru Kanaya, Koh Izumiyama, Makoto Saito, Masanobu Morioka, Akio Mori, Takeshi Kondo   +10 more
wiley   +1 more source

Clinical features, central nervous system risk, and therapeutic outcomes in primary sinonasal diffuse large B-cell lymphoma: a retrospective cohort study of 94 patients. [PDF]

Transl Cancer Res
Yao N, Wang C, Niu M, Yang L, Cong J, Ye J, Li X, Yang J, Wei L, Wang L.   +9 more
europepmc   +1 more source

Successful propranolol therapy for infantile hepatic hemangioma with cardiac failure

JPGN Reports, Volume 7, Issue 3, Page 387-390, August 2026.
Abstract Infantile hepatic hemangioma (IHH) can cause severe complications such as high‐output cardiac failure and growth faltering, requiring prompt diagnosis and intervention. In the absence of standardized treatment guidelines, propranolol has emerged as an effective and well‐tolerated therapy.
Fadhel Al Ateeqi, Ala K. Shaikhkhalil, Haitham Talo, Naeem Jagirdar, Mahdia AL‐Haidar   +4 more
wiley   +1 more source

Successful management approach for Wilms tumor metastatic to the skull treated with regimen I chemotherapy in 10th week: A case report. [PDF]

Urol Case Rep
Prasetyawan B, Seputra KP, Nurhadi P.
europepmc   +1 more source

Chronotherapy in Hematological Malignancies: Evaluating the Rationale and Evidence

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Hematological malignancies remain one of the leading causes of morbidity and mortality despite advances in targeted therapies, immunotherapy, and stem cell transplantation. Emerging evidence indicates that treatment efficacy and toxicity depend not only on the choice of therapy but also on its timing relative to the patient's internal ...
Andrej Belančić, Marko Skelin, Yun Wah Lam, Almir Fajkić, Bruna Perkov‐Stipičin, Rossana Roncato, Ivan Krečak, Marko Lucijanić   +7 more
wiley   +1 more source

Distortion product otoacoustic emission (DPOAE) reveals hearing loss up to 16 kHz in pediatric chemotherapy patients. [PDF]

Sci Rep
Hecker DJ, Remke MKH, Linxweiler M, Furtwängler R, Akrasu Y, Schöndorf D, Graf N, Krieter D, Oberkircher N, Schick B, Bozzato A, Simon A.   +11 more
europepmc   +1 more source

Extrapolating Vincristine‐Induced Peripheral Neuropathy From Caucasian to Kenyan Populations: Impact of Type I and Type II Selection Bias

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 8, August 2026.
ABSTRACT Vincristine is a cornerstone of pediatric chemotherapy, but its use is limited by vincristine‐induced peripheral neuropathy (VIPN). Paradoxically, African children tolerate higher vincristine doses with minimal neurotoxicity, raising questions about the pharmacological mechanisms and model generalizability across populations. In this study, we
Maddalena Centanni, Mirjam Esther van de Velde, Alwin D. R. Huitema, Gertjan L. Kaspers, Mats O. Karlsson, Lena E. Friberg   +5 more
wiley   +1 more source

Adult-onset refractory retroperitoneal neuroblastoma with diagnostic and therapeutic challenges: a case report and review of literature. [PDF]

J Med Case Rep
Karna NK, Pokhrel G, Osti A, Neupane N, Pokhrel P, Bhattarai K, Ray R, Khanal S, Sharma R, Dulal S.   +9 more
europepmc   +1 more source

Efficacy of Adjuvant Interferon‐β Versus Observation for Resected Nail Apparatus Melanoma: A Multicenter Retrospective Study

The Journal of Dermatology, Volume 53, Issue 8, Page 1124-1132, August 2026.
ABSTRACT Nail apparatus melanoma (NAM) is a biologically and clinically distinct subtype of melanoma; however, the efficacy of adjuvant interferon (IFN) therapy in this population remains unclear. We conducted a multicenter retrospective study to compare adjuvant IFN‐β (adj‐IFN) with observation (OBS) in patients with resected stage IIB, IIC, or III ...
Takaya Komori, Eiji Nakano, Yukiko Kiniwa, Shoichiro Mori, Sotaro Yamamoto, Hiroshi Kato, Shusuke Yoshikawa, Koji Yoshino, Megumi Aoki, Tatsuya Takenouchi, Takuya Maeda, Keijun Yoshino, Shuichi Ohe, Kenta Nakama, Hideyuki Ishikawa, Yoshiyuki Nakamura, Toshihiro Takai, Takamichi Ito, Hiroshi Kitagawa, Hiraku Kokubu, Naohito Hatta, Takeru Funakoshi, Toshihiko Hoashi, Takayuki Suyama, Susumu Fujiwara, Mamiko Masuzawa, Hiroshi Uchi, Takuya Miyagawa, Soichiro Kado, Yuki Yamamoto, Jun Asai, Junji Kato, Taku Maeda, Natsuki Baba, Yukihiko Kato, Kohei Oashi, Takeo Maekawa, Shunichi Jinnai, Aya Nishizawa, Ko Kagoyama, Atsushi Otsuka, Katsuhiko Nishihara, Dai Ogata, Kenjiro Namikawa, Yasuhiro Nakamura, Shigeto Matsushita   +45 more
wiley   +1 more source

Advanced Stage Hodgkin Lymphoma: A Review on Frontline Treatment Advances. [PDF]

Cancer J
Baron K, Hu B.
europepmc   +1 more source